References
- Barth E, Stammler G, Speiser B, et al. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol. 1992;24:669–681. Available from: http://dx.doi.org/10.1016/0022-2828(92)93381-S doi:10.1016/0022-2828(92)93381-S. PMID:1404407
- Rosca MG, Hoppel CL. Mitochondrial dysfunction in heart failure. Heart Fail Rev. 2013;18:607–622. Available from: http://dx.doi.org/10.1007/s10741-012-9340-0 doi:10.1007/s10741-012-9340-0. PMID:22948484
- Marin-Garcia J, Akhmedov AT, Moe GW. Mitochondria in heart failure: the emerging role of mitochondrial dynamics. Heart Fail Rev. 2013;18:439–456. Available from: http://dx.doi.org/10.1007/s10741-012-9330-2 doi:10.1007/s10741-012-9330-2. PMID:22707247
- Chaban Y, Boekema EJ, Dudkina NV. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta. 2014;1837:418–426. Available from: http://dx.doi.org/10.1016/j.bbabio.2013.10.004 doi:10.1016/j.bbabio.2013.10.004. PMID:24183696
- Sharov VG, Todor AV, Silverman N, et al. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol. 2000;32:2361–2367. Available from: http://dx.doi.org/10.1006/jmcc.2000.1266 doi:10.1006/jmcc.2000.1266. PMID:11113011
- Sabbah HN. Targeting mitochondrial dysfunction in the treatment of heart failure. Expert Rev Cardiovasc Ther. 2016;14:1305–1313. Available from: http://dx.doi.org/10.1080/14779072.2016.1249466 doi:10.1080/14779072.2016.1249466. PMID:27758146
- Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol. 2013;61:599–610. Available from: http://dx.doi.org/10.1016/j.jacc.2012.08.1021 doi:10.1016/j.jacc.2012.08.1021. PMID:23219298
- Brown DA, Perry JB, Allen ME, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14:238–250. Available from: http://dx.doi.org/10.1038/nrcardio.2016.203 doi:10.1038/nrcardio.2016.203. PMID:28004807
- Abend A, Kehat I. Histone deacetylases as therapeutic targets–from cancer to cardiac disease. Pharmacol Ther. 2015;147:55–62. Available from: http://dx.doi.org/10.1016/j.pharmthera.2014.11.003 doi:10.1016/j.pharmthera.2014.11.003. PMID:25444758
- Hewitson R, Dargan J, Collis D, et al. Heart failure: the pivotal role of histone deacetylases. Int J Biochem Cell Biol. 2013;45:448–453. Available from: http://dx.doi.org/10.1016/j.biocel.2012.11.006 doi:10.1016/j.biocel.2012.11.006. PMID:23178536
- Aune SE, Herr DJ, Kutz CJ, et al. Histone deacetylases exert class-specific roles in conditioning the brain and heart against acute ischemic injury. Front Neurol. 2015;6:145. Available from: http://dx.doi.org/10.3389/fneur.2015.00145 doi:10.3389/fneur.2015.00145. PMID:26175715
- Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell. 2008;31:449–461. Available from: http://dx.doi.org/10.1016/j.molcel.2008.07.002 doi:10.1016/j.molcel.2008.07.002. PMID:18722172
- McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol. 2012;52:303–319. Available from: http://dx.doi.org/10.1146/annurev-pharmtox-010611-134712 doi:10.1146/annurev-pharmtox-010611-134712. PMID:21942627
- McKinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med. 2011;17:434–441. Available from: http://dx.doi.org/10.2119/molmed.2011.00022 doi:10.2119/molmed.2011.00022. PMID:21267510
- Kao YH, Liou JP, Chung CC, et al. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol. 2013;168:4178–4183. Available from: http://dx.doi.org/10.1016/j.ijcard.2013.07.111 doi:10.1016/j.ijcard.2013.07.111. PMID:23931972
- Galmozzi A, Mitro N, Ferrari A, et al. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes. 2013;62:732–742. Available from: http://dx.doi.org/10.2337/db12-0548 doi:10.2337/db12-0548. PMID:23069623
- Ueland T, Gullestad L, Nymo SH, et al. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015;443:71–77. Available from: http://dx.doi.org/10.1016/j.cca.2014.09.001 doi:10.1016/j.cca.2014.09.001. PMID:25199849
- Dunlay SM, Weston SA, Redfield MM, et al. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625–631. Available from: http://dx.doi.org/10.1161/circulationaha.107.759191 doi:10.1161/CIRCULATIONAHA.107.759191. PMID:18645056
- Babu D, Leclercq G, Goossens V, et al. Mitochondria and NADPH oxidases are the major sources of TNF-alpha/cycloheximide-induced oxidative stress in murine intestinal epithelial MODE-K cells. Cell Signal. 2015;27:1141–1158. Available from: http://dx.doi.org/10.1016/j.cellsig.2015.02.019 doi:10.1016/j.cellsig.2015.02.019. PMID:25725292
- Doll DN, Rellick SL, Barr TL, et al. Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. J Neurochem. 2015;132:443–451. Available from: http://dx.doi.org/10.1111/jnc.13008 doi:10.1111/jnc.13008. PMID:25492727
- Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35:537–544. Available from: http://dx.doi.org/10.1016/s0735-1097(99)00600-2 doi:10.1016/S0735-1097(99)00600-2. PMID:10716453
- Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391. Available from: http://dx.doi.org/10.1161/01.CIR.97.14.1382 doi:10.1161/01.CIR.97.14.1382. PMID:9577950
- Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487–1493. Available from: http://dx.doi.org/10.1161/01.CIR.92.6.1487 doi:10.1161/01.CIR.92.6.1487. PMID:7664431
- Mariappan N, Elks CM, Fink B, et al. TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction. Free Radic Biol Med. 2009;46:462–470. Available from: http://dx.doi.org/10.1016/j.freeradbiomed.2008.10.049 doi:10.1016/j.freeradbiomed.2008.10.049. PMID:19041937
- Prajapati P, Sripada L, Singh K, et al. TNF-alpha regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells. Biochim Biophys Acta. 2015;1852:451–461. Available from: http://dx.doi.org/10.1016/j.bbadis.2014.11.019 doi:10.1016/j.bbadis.2014.11.019. PMID:25481834
- Kawabata T, Nishida K, Takasugi K, et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther. 2010;12:R133. Available from: http://dx.doi.org/10.1186/ar3071 doi:10.1186/ar3071. PMID:20609223
- Lkhagva B, Lin YK, Kao YH, et al. Novel histone deacetylase inhibitor modulates cardiac peroxisome proliferator-activated receptors and inflammatory cytokines in heart failure. Pharmacology. 2015;96:184–191. Available from: http://dx.doi.org/10.1159/000438864 doi:10.1159/000438864. PMID:26304494
- Keslacy S, Tliba O, Baidouri H, et al. Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol Pharmacol. 2007;71:609–618. Available from: http://dx.doi.org/10.1124/mol.106.030171 doi:10.1124/mol.106.030171. PMID:17108260
- Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci U S A. 2003;100:14742–14747. Available from: http://dx.doi.org/10.1073/pnas.2433987100 doi:10.1073/pnas.2433987100. PMID:14645718
- Gang H, Shaw J, Dhingra R, et al. Epigenetic regulation of canonical TNFalpha pathway by HDAC1 determines survival of cardiac myocytes. Am J Physiol Heart Circ Physiol. 2013;304:H1662–H1669. Available from: http://dx.doi.org/10.1152/ajpheart.00093.2013 doi:10.1152/ajpheart.00093.2013. PMID:23585133
- Vashisht Gopal YN, Arora TS, Van Dyke MW. Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2. EMBO Rep. 2006;7:291–296. Available from: http://dx.doi.org/10.1038/sj.embor.7400613 doi:10.1038/sj.embor.7400613. PMID:16374504
- Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol. 2011;31:233–263. Available from: http://dx.doi.org/10.1615/CritRevImmunol.v31.i3.40 doi:10.1615/CritRevImmunol.v31.i3.40. PMID:21740352
- Toussirot E, Abbas W, Khan KA, et al. Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production. PLoS One. 2013;8:e70939. Available from: http://dx.doi.org/10.1371/journal.pone.0070939 doi:10.1371/journal.pone.0070939. PMID:24039666
- Rosca MG, Hoppel CL. New aspects of impaired mitochondrial function in heart failure. J Bioenerg Biomembr. 2009;41:107–112. Available from: http://dx.doi.org/10.1007/s10863-009-9215-9 doi:10.1007/s10863-009-9215-9. PMID:19347572
- Sharma LK, Lu J, Bai Y. Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr Med Chem. 2009;16:1266–1277. Available from: http://dx.doi.org/10.2174/092986709787846578 doi:10.2174/092986709787846578. PMID:19355884
- Finley LW, Haas W, Desquiret-Dumas V, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One. 2011;6:e23295. Available from: http://dx.doi.org/10.1371/journal.pone.0023295 doi:10.1371/journal.pone.0023295. PMID:21858060
- Canettieri G, Morantte I, Guzman E, et al. Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nat Struct Biol. 2003;10:175–181. Available from: http://dx.doi.org/10.1038/nsb895 doi:10.1038/nsb895. PMID:12567184
- Gregoire S, Xiao L, Nie J, et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol. 2007;27:1280–1295. Available from: http://dx.doi.org/10.1128/mcb.00882-06 doi:10.1128/MCB.00882-06. PMID:17158926
- Handschin C, Rhee J, Lin J, et al. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci U S A. 2003;100:7111–7116. Available from: http://dx.doi.org/10.1073/pnas.1232352100 doi:10.1073/pnas.1232352100. PMID:12764228
- Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 2014;94:909–950. Available from: http://dx.doi.org/10.1152/physrev.00026.2013 doi:10.1152/physrev.00026.2013. PMID:24987008
- Kao YH, Chen YC, Cheng CC, et al. Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med. 2010;38:217–222. Available from: http://dx.doi.org/10.1097/CCM.0b013e3181b4a854 doi:10.1097/CCM.0b013e3181b4a854. PMID:19730253
- Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409:581–589. Available from: http://dx.doi.org/10.1042/bj20070779 doi:10.1042/BJ20070779. PMID:17868033
- Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc. 2003;125:5586–5587. Available from: http://dx.doi.org/10.1021/ja0341440 doi:10.1021/ja0341440. PMID:12733869